Q32 Bio (NASDAQ:QTTB) CFO Lee Kalowski Sells 1,301 Shares of Stock

Q32 Bio Inc. (NASDAQ:QTTB) CFO Lee Kalowski sold 1,301 shares of the business’s stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $8.32, for a total transaction of $10,824.32. Following the completion of the transaction, the chief financial officer owned 137,170 shares in the company, valued at approximately $1,141,254.40. The trade was a 0.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lee Kalowski also recently made the following trade(s):

• On Tuesday, August 25th, Lee Kalowski sold 3,972 shares of Q32 Bio stock. The stock was sold at an average price of $16.56, for a total transaction of $65,776.32.

Q32 Bio Trading Down 0.6%

Shares of NASDAQ:QTTB traded down $0.05 during mid-day trading on Wednesday, reaching $8.01. The company had a trading volume of 889,313 shares, compared to its average volume of 781,863. The firm has a market cap of $238.46 million, a price-to-earnings ratio of 2.67 and a beta of 0.31. The company’s 50-day moving average price is $12.08 and its 200-day moving average price is $10.88. Q32 Bio Inc. has a one year low of $1.90 and a one year high of $23.57.

Q32 Bio (NASDAQ:QTTB) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.02. On average, research analysts anticipate that Q32 Bio Inc. will post -1.54 EPS for the current fiscal year.

Analyst Ratings Changes

QTTB has been the subject of several recent research reports. Leerink Partners assumed coverage on Q32 Bio in a report on Monday. They issued an “outperform” rating and a $40.00 price objective for the company. Morgan Stanley began coverage on shares of Q32 Bio in a report on Monday, August 24th. They set an “overweight” rating and a $34.00 price objective on the stock. HC Wainwright boosted their price target on shares of Q32 Bio from $13.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, July 28th. Oppenheimer restated an “outperform” rating on shares of Q32 Bio in a research note on Thursday, October 1st. Finally, Mizuho raised shares of Q32 Bio to a “strong-buy” rating in a report on Monday, September 7th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $32.17.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in QTTB. Cetera Investment Advisers bought a new stake in shares of Q32 Bio during the first quarter valued at about $133,000. ADAR1 Capital Management LLC boosted its position in shares of Q32 Bio by 75.0% in the first quarter. ADAR1 Capital Management LLC now owns 35,000 shares of the company’s stock valued at $225,000 after acquiring an additional 15,000 shares during the period. Susquehanna International Group LLP bought a new position in shares of Q32 Bio in the second quarter valued at approximately $297,000. Squarepoint Ops LLC purchased a new position in Q32 Bio during the second quarter valued at approximately $303,000. Finally, Carlyle Group Inc. purchased a new position in Q32 Bio during the second quarter valued at approximately $769,000. Hedge funds and other institutional investors own 31.32% of the company’s stock.

Q32 Bio Company Profile

Q32 Bio is a clinical-stage biotechnology company focused on developing therapies designed to restore immune homeostasis and address diseases driven by immune dysregulation. The company’s approach targets pathways involved in the transforming growth factor beta superfamily, which plays a role in regulating inflammation, tissue repair and immune responses.

Q32 Bio’s lead product candidate is bempikibart, also known as ADX-914, a fully human monoclonal antibody designed to modulate immune activity through selective targeting of the activin receptor type IIA pathway.